文献速递前列腺癌

转移性去势抵抗性前列腺癌患者接受恩扎卢胺治疗期间系列正电子发射断层成像的定量分析

Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide.
PubMed 文献 · Eur Urol Oncol · 2023-10-17

在美国国家癌症研究所一项临床试验中,18例转移性去势抵抗性前列腺癌患者接受恩扎卢胺一线治疗,共进行67次18F-氟化钠(NaF)PET扫描。定量分析显示,治疗后233个感兴趣区中52个(22%)最终消退后复现,394个新感兴趣区中112个(28%)随后消退。作者认为NaF PET表现动态变化,并非所有新发现均与疾病进展相关,并提示用PET判断是否需更换治疗时应谨慎。

要点

  • 18例患者共67次NaF PET扫描,233个感兴趣区治疗后消退,其中52个(22%)最终复现。
  • 394个新感兴趣区中112个(28%)随后消退,18例中14例新感兴趣区最终消退。
  • 作者提示用PET影像判断是否需更换治疗时应谨慎。

核心结论

  • NaF PET在恩扎卢胺治疗的mCRPC患者中表现动态变化,并非所有新发现最终均与疾病进展相关,该分析提供了识别和干预前列腺癌寡进展的潜在策略。

研究设计与样本

  • 事后描述性分析,患者来自美国国家癌症研究所(Bethesda, MD, USA)一项临床试验,均为恩扎卢胺一线治疗的mCRPC患者。
  • 志愿者样本接受系列18F-氟化钠(NaF)PET,并与CT和锝-99m(Tc99)骨扫描平行进行,对NaF感兴趣区(ROI)进行定量应答分析。
  • 患者随机接受恩扎卢胺联合或不联合癌症免疫治疗Prostvac。

主要发现

  • 18例mCRPC患者共接受67次NaF扫描。
  • 治疗后233个ROI消退,其中52个(22%)在治疗期间最终复现。
  • 共见394个新ROI,其中112个(28%)随后消退。
  • 18例患者中14例出现的新ROI最终消退。
  • 许多患者仅少数病灶进展,1例接受放疗干预寡进展的患者获得显著反应。

关键数值与推荐

  • CT和Tc99按RECIST 1.1评估的变化与NaF PET扫描进行比较,包括定量分析。
  • 233个ROI消退后52个(22%)复现;394个新ROI中112个(28%)消退。

临床怎么用

  • 作者提示,使用PET影像判断是否需要新治疗时应谨慎。
  • 作者认为该分析提供了识别和干预前列腺癌寡进展的潜在策略。

局限性

  • 研究受患者数量少限制。
  • 研究为事后分析性质。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The emergence of positron emission tomography (PET) in prostate cancer is impacting clinical practice, but little is known about PET imaging as a tool to determine treatment failure in metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE: To evaluate PET imaging dynamics in mCRPC patients on enzalutamide with stable computed tomography (CT) and technetium-99m (Tc99) bone scans. DESIGN, SETTING, AND PARTICIPANTS: All patients were on treatment with enzalutamide for first-line mCRPC in a clinical trial at the National Cancer Institute (Bethesda, MD, USA). A volunteer sample had serial 18F-sodium fluoride (NaF) PET in parallel with CT and Tc99. Regions of interest (ROIs) on NaF were analyzed quantitatively for response. INTERVENTION: Patients were randomized to enzalutamide with/without a cancer immunotherapy, Prostvac. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A post hoc, descriptive analysis was performed comparing the changes seen on CT and Tc99 as per RECIST 1.1 with NaF PET scans including the use of a quantitative analysis. RESULTS AND LIMITATIONS: Eighteen mCRPC patients had 67 NaF scans. A total of 233 ROIs resolved after treatment, 52 (22%) of which eventually retuned while on therapy. In all, 394 new ROIs were seen, but 112(28%) resolved subsequently. Of 18 patients, 14 had new ROIs that ultimately resolved after appearing. Many patients experienced progression in a minority of lesions, and one patient with radiation intervention to oligoprogression had a remarkable response. This study is limited by its small number of patients and post hoc nature. CONCLUSIONS: These data highlight the dynamic nature of NaF PET in mCRPC patients treated with enzalutamide, where not all new findings were ultimately related to disease progression. This analysis also provides a potential strategy to identify and intervene in oligoprogression in prostate cancer. PATIENT SUMMARY: In this small analysis of patients with prostate cancer on enzalutamide, changes on 18F-sodium fluoride positron emission tomography (PET) imaging were not always associated with treatment failure. Caution may be indicated when using PET imaging to determine whether new therapy is needed.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Gandhy SU, Karzai FH, Bilusic M, et al. Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide. Eur Urol Oncol. 2023. PMID: 37858437. doi:10.1016/j.euo.2023.09.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。